Drug Trial News

RSS

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

A clinical trial of a new investigational vaccine designed to protect against West Nile Virus infection will be sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

7 Jul 2015

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.

7 Jul 2015

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.

7 Jul 2015

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim today announced The Lancet Oncology has published results from the LUX-Lung 8 trial. LUX-Lung 8 is the largest, prospective Phase III head-to-head trial directly comparing two EGFR-directed treatments.

6 Jul 2015

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies.

6 Jul 2015

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

3 Jul 2015

Gene therapy for cystic fibrosis shows significant benefit in lung function

For the first time gene therapy for cystic fibrosis has shown a significant benefit in lung function compared with placebo, in a phase 2 randomised trial published in The Lancet Respiratory Medicine journal. The technique replaces the defective gene response for cystic fibrosis by using inhaled molecules of DNA to deliver a normal working copy of the gene to lung cells.

3 Jul 2015

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

A novel synthetic hormone that makes certain skin cells produce more melanin significantly increases pain-free sun exposure in people with erythropoietic protoporphyria, a rare, genetic disorder resulting in excruciating pain within minutes of sun exposure.

3 Jul 2015

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active.

2 Jul 2015

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

Avexxin AS, a therapeutic company focusing on the discovery and development of novel small molecule therapeutics for patients suffering from chronic inflammatory conditions, announces the completion of a second phase I/IIa study showing Proof-of-Concept in man.

2 Jul 2015

24% rise in the number of clinical trials according to Cell Therapy Catapult annual UK analysis

The Cell Therapy Catapult has published its annual analysis of the UK preclinical and clinical research landscapes with the release of its UK Clinical and Pre-Clinical Trials Databases. These show a 24% rise in the number of clinical trials and an increase of 22% in the number of pre-clinical projects. Sector growth came in the key areas of oncology, neurology, ophthalmology and cardiovascular.

2 Jul 2015

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, antiemetics expert and ESMO spokesperson Fausto Roila said, putting into perspective the results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

2 Jul 2015

UCSD researchers report that statins make women aggressive, but men calmer

Statins are a hugely popular drug class used to manage blood cholesterol levels and reduce the risk of heart disease. Previous studies had raised questions about adverse behavioral changes with statins, such as irritability or violence, but findings with statins have been inconsistent. In the first randomized trial to look at statin effects on behavior, researchers at the University of California, San Diego School of Medicine report that aggressive behavior typically declined among men placed on statins (compared to placebo), but typically increased among women placed on statins.

2 Jul 2015

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Researchers at Spectrum Health Helen DeVos Children's Hospital have completed the first clinical trial of a new treatment for children suffering from neuroblastoma. In a clinical trial led by Giselle Sholler, MD, pediatric oncologist at Helen DeVos Children's Hospital and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), DFMO, an investigational agent, showed minimal side effects with long-term survival of three patients.

2 Jul 2015

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the development of groundbreaking drugs to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), announced today that Robert G. Miller, M.D., Director of the Forbes Norris MDA/ALS Research Center at Sutter Health's California Pacific Medical Center in San Francisco, has been awarded a grant from The ALS Association for $1.5 million to help fund a Phase 2 clinical study of the company's investigational therapy for ALS, NP001.

1 Jul 2015

ALS ACT initiative to speed discovery of new ALS treatments

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) initiative.

1 Jul 2015

Pinaverium offers quick relief from IBS symptoms

Pinaverium offers quick and effective relief of irritable bowel syndrome (IBS) symptoms, according to clinical trial results published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Jun 2015

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company's Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson's Disease (PD).

30 Jun 2015

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.

30 Jun 2015

Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration.

30 Jun 2015

Drug Trial News

NIH-sponsored clinical trial evaluates new investigational vaccine against West Nile Virus infection

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Celtaxsys receives FDA clearance to begin acebilustat Phase 2 trial in adult CF patients in the US

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

Gene therapy for cystic fibrosis shows significant benefit in lung function

Afamelanotide treatment improves quality of life in people with erythropoietic protoporphyria

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Avexxin concludes second phase I/IIA study in patients suffering from mild-to-moderate psoriasis

24% rise in the number of clinical trials according to Cell Therapy Catapult annual UK analysis

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

UCSD researchers report that statins make women aggressive, but men calmer

Researchers complete phase 1 clinical trial of new drug for children suffering from neuroblastoma

Robert G. Miller awarded $1.5 million grant to help fund Neuraltus' Phase 2 clinical study of NP001 for ALS

ALS ACT initiative to speed discovery of new ALS treatments

Pinaverium offers quick relief from IBS symptoms

Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Latest News